As the curtains fell on the latest trading session, Thermo Fisher Scientific (TMO) stood at $580.05 apiece, marking a slight dip of -0.7% from the previous day. Despite this descent, it paled in comparison to the S&P 500’s 0.63% daily ascent. In parallel, the industrious Dow climbed 0.2%, and the tech-savvy Nasdaq surged by 0.82%.
Over the last month, the shares of this bastion of scientific instruments and laboratory supplies have flourished by 6.63%, outshining the Medical sector’s 0.91% gain and the S&P 500’s 1.76% rise.
With bated breath, investors await Thermo Fisher Scientific’s upcoming earnings release. Prognostications foretell earnings of $4.71 per share, a 6.36% drop from the previous year. Concurrently, analysts anticipate revenue of $10.14 billion, prefacing a 5.28% decline vis-à-vis the corresponding quarter in the prior year.
Zooming out to the full year, Zacks Consensus Estimates envision earnings of $21.52 per share and revenue of $42.74 billion, reflecting variations of -0.14% and -0.28%, respectively, compared to the preceding year.
Noteworthy shifts in analyst projections surrounding Thermo Fisher Scientific may catch investors’ discerning eyes. These revisions mirror prevailing short-term business trajectories, with positive revisions signaling analysts’ faith in the company’s operations and profitability.
Research indicates that these adjustments harmonize harmoniously with immediate stock prices. Savvy investors could seize this opportunity by leveraging the Zacks Rank. This ranking system factors in these estimate fluctuations, furnishing a discernible, actionable assessment.
The Zacks Rank scale, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts a storied record of outpacing benchmarks, substantiated by external audits. Since 1988, #1 stocks have yielded an average annual profit of +25%. Recent data shows Zacks Consensus EPS estimate remaining steady. Presently, Thermo Fisher Scientific proudly bears a Zacks Rank of #3 (Hold).
Eyeing Thermo Fisher Scientific’s prevailing valuation metrics, investors would do well to consider its Forward P/E ratio of 27.14. Notably, this valuation sits at a modest discount relative to the industry’s average Forward P/E of 27.51.
Furthermore, TMO presently sports a PEG ratio of 2.45. This widely recognized metric mirrors the famed P/E ratio, albeit encompassing the company’s anticipated earnings growth rate. As trading concluded yesterday, the Medical – Instruments industry wielded an average PEG ratio of 2.24.
In the broader realm of the Medical sector, the Medical – Instruments industry captures attention. Boasting a current Zacks Industry Rank of 54, this sector luxuriates in the top 22% of all industries, outstripping over 250 counterparts.
The Zacks Industry Rank acts as a barometer, measuring the industry groups’ robustness by aggregating the individual stocks’ average Zacks Rank. Our analysis spotlights that the top 50% rated industries outpace the bottom half—a disparity of 2 to 1.
For additional insight into these metrics and more, visit Zacks.com.
Construction Stock Surge Poised to Overwhelm America
A massive endeavor to revamp decrepit U.S. infrastructure looms on the horizon. Spanning bipartisan lines, this endeavor, urgent and imperative, foretells a colossal expenditure. Within this milieu, fortunes are poised for the taking.
The burning question remains, “Will you stake a claim on the correct stocks early, when their growth potential is most prolific?”
Zacks has unveiled a Special Report poised to guide you in this venture, and this very day, it’s complimentary. Explore 5 exceptional companies primed to thrive amidst renovations and refurbishments of roads, bridges, structures, alongside cargo hauling and energy transformation on an epic scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Seeking the freshest insights from Zacks Investment Research? Today, secure your copy of 7 Best Stocks for the Next 30 Days. Click to access this comprehensive report
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
To view this article on Zacks.com, click here.
Zacks Investment Research
Opinions and views expressed here represent the author’s sentiments and not necessarily those of Nasdaq, Inc.
